Jason Potts, MD
Internal Medicine · Lincoln, NENPI 1215940358
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $603 of the $703 with a category attached, or 85.8%. It is spread thinly across 21 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations.
Across 37 payments — averaging $18.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$129
- Optinose US, Inc.$89
- Pfizer$71
- Novo Nordisk$57
- AbbVie$46
- Amgen$43
- plus $268 from 15 others
Across 11 payments — averaging $62,302 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$685K
What the payments were for
- Food & beverage$60386%
- Education$10014%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 2 | $129 |
| Optinose US, Inc. | 4 | $89 |
| Pfizer | 4 | $71 |
| Novo Nordisk | 3 | $57 |
| AbbVie | 2 | $46 |
| Amgen | 3 | $43 |
| AstraZeneca | 3 | $36 |
| Sanofi Pasteur Inc. | 2 | $34 |
| Lilly USA, LLC | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Antares Pharma, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
| GSK | 1 | $13 |
| Bayer | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Jazz Pharmaceuticals Inc. | 1 | $11 |
How this compares
$703 in reported general payments places this provider in the 75th percentile of 570 internal medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 131 | $116,255 |
| XareltoRivaroxaban | 115 | $89,031 |
| JardianceEmpagliflozin | 55 | $45,727 |
| FarxigaDapagliflozin Propanediol | 46 | $42,707 |
| MyrbetriqMirabegron | 44 | $32,411 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $25,943 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 30 | $23,875 |
| JanuviaSitagliptin Phosphate | 23 | $22,792 |
| OzempicSemaglutide | 14 | $20,632 |
| MounjaroTirzepatide | 12 | $17,419 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $10,147 |
| EntrestoSacubitril/Valsartan | 12 | $8,396 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $7,156 |
| CreonLipase/Protease/Amylase | 11 | $6,568 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $5,908 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $71 | $119,113149 claims |
| AstraZenecaFarxiga, Symbicort | $36 | $49,86364 claims |
| Boehringer IngelheimJardiance | $15 | $45,72755 claims |
| Astellas Pharma US IncMyrbetriq | $129 | $32,41144 claims |
| Novo NordiskOzempic | $57 | $20,63214 claims |
| Lilly USA, LLCMounjaro | $29 | $17,41912 claims |
| AbbVieCreon, Synthroid | $46 | $11,36385 claims |
| GSKAnoro Ellipta | $13 | $10,14717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 570 internal medicine providers in Nebraska.
Other internal medicine in Lincoln
- Sherri ThomasLincoln$136K
- Aaron WardLincoln$15K
- Anthony RossLincoln$6K
- Wasim ChughtaiLincoln$6K
- Mary DreyLincoln$6K
- Alexander RyanLincoln$5K
- James FosnaughLincoln$3K
- Brian BoerOmaha$142K
- Adam BurdorfOmaha$29K
- David SharpOmaha$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.